Development of effective vaccines for old mice in a tumor model

Vaccine

Volumn 27, Issue 7, 2009, Pages 1093-1100

  Posnett, David N ^a,b   Engelhorn, Manuel E ^b   Lin, Yun ^b   Merghoub, Taha ^b   Duan, Fei ^b   Wolchok, Jedd D ^b   Houghton, Alan N ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antigen presentation processing; Immunodeficiency of aging; Rodent; Tumor immunity; Vaccination

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OUTER MEMBRANE PROTEIN A; PROTEIN VP22; TOLL LIKE RECEPTOR 2; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1EE OMPA VACCINE; TYROSINASE RELATED PROTEIN 1EE VACCINE; TYROSINASE RELATED PROTEIN 1EE VP22 VACCINE; UNCLASSIFIED DRUG;

AGE; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; ESCHERICHIA COLI; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNODEFICIENCY OF AGING; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT; TUMOR IMMUNITY; TUMOR MODEL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; BACTERIAL OUTER MEMBRANE PROTEINS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; INTERFERON-GAMMA; MELANOMA; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; VIRAL STRUCTURAL PROTEINS;

EID: 58549100513     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.112     Document Type: Article

References (41)

1. Aspinall R., Henson S.M., and Pido-Lopez J. My T's gone cold, I'm wondering why. Nat Immunol 4 3 (2003) 203-205
2. Engelhorn M.E., Guevara-Patino J.A., Noffz G., Hooper A.T., Lou O., Gold J.S., et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 12 2 (2006) 198-206
3. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 4 (2003) 1284-1290
4. Conry R.M., Curiel D.T., Strong T.V., Moore S.E., Allen K.O., Barlow D.L., et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8 9 (2002) 2782-2787
5. Stan R., Wolchok J.D., and Cohen A.D. DNA vaccines against cancer. Hematol Oncol Clin North Am 20 3 (2006) 613-636
6. Guevara-Patino J.A., Engelhorn M.E., Turk M.J., Liu C., Duan F., Rizzuto G., et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 116 5 (2006) 1382-1390
7. Engelhorn M.E., Guevara-Patiño J.A., Merghoub T., Liu C., Ferrone C.R., Rizzuto G.A., et al. Mechanisms of immunization against cancer using chimeric antigens. Mol Ther 16 4 (2008) 773-781
8. Dyall R., Bowne W.B., Weber L.W., LeMaoult J., Szabo P., Moroi Y., et al. Heteroclitic immunization induces tumor immunity. J Exp Med 188 9 (1998) 1553-1561
9. Scheibenbogen C., Lee K.H., Mayer S., Stevanovic S., Moebius U., Herr W., et al. A sensitive ELISPOT assay for detection of CD8+T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3 2 (1997) 221-226
10. Flood P.M., Urban J.L., Kripke M.L., and Schreiber H. Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med 154 2 (1981) 275-290
11. Flood P.M., Liu X., Alexander R., Schreiber H., and Haque S. Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity. J Immunother 21 4 (1998) 307-316
12. Urban J.L., and Schreiber H. Rescue of the tumor-specific immune response of aged mice in vitro. J Immunol 133 1 (1984) 527-534
13. Win S., Uenaka A., and Nakayama E. Immune responses against allogeneic and syngeneic tumors in aged C57BL/6 mice. Microbiol Immunol 46 7 (2002) 513-519
14. Provinciali M., Argentati K., and Tibaldi A. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7 7 (2000) 624-632
15. Provinciali M., Smorlesi A., Donnini A., Bartozzi B., and Amici A. Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21 9-10 (2003) 843-848
16. Kaptzan T., Skutelsky E., Itzhaki O., Sinai J., Michowitz M., Yossipov Y., et al. Age-dependent differences in the efficacy of cancer immunotherapy in C57BL and AKR mouse strains. Exp Gerontol 39 7 (2004) 1035-1048
17. Jeannin P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Delneste Y., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 1 6 (2000) 502-509
18. Sciortino M.T., Taddeo B., Poon A.P., Mastino A., and Roizman B. Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc Natl Acad Sci USA 99 12 (2002) 8318-8323
19. Bennett R.P., Dalby B., and Guy P.M. Protein delivery using VP22. Nat Biotechnol 20 1 (2002) 20
20. Lundberg M., Wikstrom S., and Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol Ther 8 1 (2003) 143-150
21. Chhabra A., Mehrotra S., Chakraborty N.G., Mukherji B., and Dorsky D.I. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur J Immunol 34 10 (2004) 2824-2833
22. Roy V., Qiao J., de Campos-Lima P., and Caruso M. Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase. Gene Ther 12 2 (2005) 169-176
23. Perkins S.D., Hartley M.G., Lukaszewski R.A., Phillpotts R.J., Stevenson F.K., and Bennett A.M. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine 23 16 (2005) 1931-1940
24. Garg S., Oran A., Wajchman J., Sasaki S., Maris C.H., Kapp J.A., et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 4 9 (2003) 907-912
25. Jeannin P., Magistrelli G., Herbault N., Goetsch L., Godefroy S., Charbonnier P., et al. Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs. Eur J Immunol 33 2 (2003) 326-333
26. Kissenpfennig A., Henri S., Dubois B., Laplace-Builhe C., Perrin P., Romani N., et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22 5 (2005) 643-654
27. Li S.P., Cai Z., Shi W., Brunmark A., Jackson M., and Linton P.J. Early antigen-specific response by naive CD8 T cells is not altered with aging. J Immunol 168 12 (2002) 6120-6127
28. Linton P.J., Haynes L., Klinman N.R., and Swain S.L. Antigen-independent changes in naive CD4 T cells with aging. J Exp Med 184 (1996) 1891-1900
29. Linton P.J., Haynes L., Tsui L., Zhang X., and Swain S. From naive to effector-alterations with aging. Immunol Rev 160 (1997) 9-18
30. Haynes L., Linton P.J., Eaton S.M., Tonkonogy S.L., and Swain S.L. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J Exp Med 190 7 (1999) 1013-1024
31. Haynes L., Eaton S.M., Burns E.M., Rincon M., and Swain S.L. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 172 9 (2004) 5194-5199
32. Bansal-Pakala P., and Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol 169 9 (2002) 5005-5009
33. Tang Y., Akbulut H., Maynard J., Petersen L., Fang X., Zhang W.W., et al. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer. J Immunol 177 8 (2006) 5697-5707
34. Sen G., Chen Q., and Snapper C.M. Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels. Infect Immun 74 4 (2006) 2177-2186
35. Qin W., Jiang J., Chen Q., Yang N., Wang Y., Wei X., et al. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice. Cell Mol Immunol 1 2 (2004) 148-152
36. Weng N.P. Aging of the immune system: how much can the adaptive immune system adapt?. Immunity 24 5 (2006) 495-499
37. Haynes L., and Swain S.L. Why aging T cells fail: implications for vaccination. Immunity 24 6 (2006) 663-666
38. Kueltzo L.A., and Middaugh C.R. Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems. J Pharm Sci 92 9 (2003) 1754-1772
39. Blouin A., and Blaho J.A. Assessment of the subcellular localization of the herpes simplex virus structural protein VP22 in the absence of other viral gene products. Virus Res 81 1-2 (2001) 57-68
40. Koelle D.M., Frank J.M., Johnson M.L., and Kwok W.W. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 72 9 (1998) 7476-7483
41. Koelle D.M., Schomogyi M., McClurkan C., Reymond S.N., and Chen H.B. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol 74 23 (2000) 11422-11425